DrugPatentWatch Database Preview
Drugs in Development Information for Palovarotene
» See Plans and Pricing
What is the drug development status for Palovarotene?
Palovarotene is an investigational drug.
There have been 9 clinical trials for Palovarotene.
The most recent clinical trial was a Phase 1 trial, which was initiated on October 1st 2017.
The most common disease conditions in clinical trials are Myositis Ossificans, Ossification, Heterotopic, and Dry Eye Syndromes. The leading clinical trial sponsors are Clementia Pharmaceuticals Inc., Ipsen, and [disabled in preview].
There are twenty-two US patents protecting this investigational drug and two hundred and four international patents.
Summary for Palovarotene
| US Patents | 22 |
| International Patents | 204 |
| US Patent Applications | 67 |
| WIPO Patent Applications | 46 |
| Japanese Patent Applications | 16 |
| Clinical Trial Progress | Phase 1 (2017-10-01) |
| Vendors | 33 |
Recent Clinical Trials for Palovarotene
| Title | Sponsor | Phase |
|---|---|---|
| Study Evaluating the Effect of Food on the Pharmacokinetics of Palovarotene and the Effect of Palovarotene on the Pharmacokinetics of the CYP3A4 Substrate Midazolam in Two Cohorts of Healthy Adult Subjects | Clementia Pharmaceuticals Inc. | Phase 1 |
| Study to Assess Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Palovarotene Ophthalmic Solution in Healthy Adult Subjects | Ipsen | Phase 1 |
| Study to Assess Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Palovarotene Ophthalmic Solution in Healthy Adult Subjects | Clementia Pharmaceuticals Inc. | Phase 1 |
Clinical Trial Summary for Palovarotene
Top disease conditions for Palovarotene
Top clinical trial sponsors for Palovarotene
US Patents for Palovarotene
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Palovarotene | Get Started for $10 | Therapeutic agent for keratoconjunctive disorders | YAMAGUCHI UNIVERSITY (Yamaguchi, JP) | Get Started for $10 |
| Palovarotene | Get Started for $10 | Controlled release dosage form | TRIASTEK, INC. (Nanjing, CN) | Get Started for $10 |
| Palovarotene | Get Started for $10 | Inhibitors of activin receptor-like kinase | BLUEPRINT MEDICINES CORPORATION (Cambridge, MA) | Get Started for $10 |
| Palovarotene | Get Started for $10 | Oral drug dosage forms having desired drug release profiles and uses thereof | Triastek, Inc. (Nanjing, CN) | Get Started for $10 |
| Palovarotene | Get Started for $10 | Composition and method for muscle repair and regeneration | Thomas Jefferson University (Philadelphia, PA) | Get Started for $10 |
| Palovarotene | Get Started for $10 | Compartmented pharmaceutical dosage forms | Triastek, Inc. (Nanjing, CN) | Get Started for $10 |
| Palovarotene | Get Started for $10 | Anti-ALK2 antibody | Saitama Medical University (Saitama, JP) Daiichi Sankyo Company, limited (Tokyo, JP) | Get Started for $10 |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Palovarotene
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Palovarotene | Australia | AU2013342882 | 2032-11-08 | Get Started for $10 |
| Palovarotene | Australia | AU2018217197 | 2032-11-08 | Get Started for $10 |
| Palovarotene | Brazil | BR112015010428 | 2032-11-08 | Get Started for $10 |
| Palovarotene | Canada | CA2890424 | 2032-11-08 | Get Started for $10 |
| Palovarotene | Chile | CL2015001225 | 2032-11-08 | Get Started for $10 |
| Palovarotene | Chile | CL2018001915 | 2032-11-08 | Get Started for $10 |
| Palovarotene | China | CN105188753 | 2032-11-08 | Get Started for $10 |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
